All-trans retinoic acid-mediated miR-30a up-regulation suppresses autophagy and sensitizes gastric cancer cells to cisplatin

Abbasi, Asadollah; Feizi, Mohammad Ali Hosseinpour; Safaralizadeh, Reza

doi:10.1016/j.lfs.2022.120884

Cited by 12 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of the gastric cancer AGS and MKN-45 cell line cells with cisplatin led to downregulation of miR-30a mRNA. Pre-incubation of these cells with ATRA increased miR-30a mRNA expression which enhanced the sensitivity of cells to growth inhibition by cisplatin and its cytotoxicity [50].…”

Section: Mir-30a Regulates Atra Biosynthesismentioning

confidence: 94%

Deregulation of All-Trans Retinoic Acid Signaling and Development in Cancer

Brown

2023

IJMS

View full text Add to dashboard Cite

Cancer stem cells are the root cause of cancer, which, in essence, is a developmental disorder. All-trans retinoic acid (ATRA) signaling via ligand-activation of the retinoic acid receptors (RARs) plays a crucial role in tissue patterning and development during mammalian embryogenesis. In adults, active RARγ maintains the pool of hematopoietic stem cells, whereas active RARα drives myeloid cell differentiation. Various findings have revealed that ATRA signaling is deregulated in many cancers. The enzymes for ATRA synthesis are downregulated in colorectal, gastric, lung, and oropharyngeal cancers. ATRA levels within breast, ovarian, pancreatic, prostate, and renal cancer cells were lower than within their normal counterpart cells. The importance is that 0.24 nM ATRA activates RARγ (for stem cell stemness), whereas 100 times more is required to activate RARα (for differentiation). Moreover, RARγ is an oncogene regarding overexpression within colorectal, cholangiocarcinoma, hepatocellular, ovarian, pancreatic, and renal cancer cells. The microRNA (miR) 30a-5p downregulates expression of RARγ, and miR-30a/miR-30a-5p is a tumor suppressor for breast, colorectal, gastric, hepatocellular, lung, oropharyngeal, ovarian, pancreatic, prostate, and renal cancer. These complementary findings support the view that perturbations to ATRA signaling play a role in driving the abnormal behavior of cancer stem cells. Targeting ATRA synthesis and RARγ has provided promising approaches to eliminating cancer stem cells because such agents have been shown to drive cell death.

show abstract

Section: Mir-30a Regulates Atra Biosynthesismentioning

confidence: 94%

Deregulation of All-Trans Retinoic Acid Signaling and Development in Cancer

Brown

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…[17,45] In combination with DDP, ATRA can increase tumor sensitivity to DDP, inhibit DDP resistance, and improve the therapeutic efficacy of DDP. [28,46] We tested for CSC-related indicators by western blotting (WB) assays and found that the expression of cluster of differentiation 44 (CD44) was significantly reduced in the DA/Pep1 group (Figure 3O and Figure S32 (Supporting Information)), indicating that the Pep1-loaded drug carrier could reduce the stemness of tumor cells.…”

Section: Effects Of the Peptide Nanocarrier Particles On The Migratio...mentioning

confidence: 99%

“…[26,27] Additionally, when combined with DDP, ATRA can increase the sensitivity of tumors to DDP, inhibit DDP resistance, and increase the effectiveness of DDP therapy. [28] However, the low plasma concentration, high systemic side effects, and physicochemical instability of ATRA, along with a lack of effective delivery systems, have limited its clinical use, and these shortcomings urgently need to be addressed. [29] In our previous studies, we designed drug-loaded smallmolecule peptides that undergo a change in primary structure and a subsequent morphological transformation in response to alkaline phosphatase and matrix metalloproteinase-2.…”

Section: Introductionmentioning

confidence: 99%

pH‐Triggered Transformable Peptide Nanocarriers Extend Drug Retention for Breast Cancer Combination Therapy

Yuan,

Liu,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Increasing the penetration and accumulation of antitumor drugs at the tumor site are crucial in chemotherapy. Smaller drug‐loaded nanoparticles (NPs) typically exhibit increased tumor penetration and more effective permeation through the nuclear membrane, whereas larger drug‐loaded NPs show extended retention at the tumor site. In addition, cancer stem cells (CSCs) have unlimited proliferative potential and are crucial for the onset, progression and metastasis of cancer. Therefore, we designed a drug‐loaded amphiphilic peptide, DA/Pep1, that self‐assembles into spherical NPs upon the encapsulation of cis‐diamminedichloroplatinum (DDP) and all‐trans retinoic acid (ATRA). In an acidic environment, DA/Pep1 transforms into aggregates containing sheet‐like structures, which significantly increases drug accumulation at the tumor site, thereby increasing antitumor effects and inhibiting metastasis. Moreover, although DDP treatment can increase the number of CSCs present, ATRA can induce the differentiation of CSCs in breast cancer to increase the therapeutic effect of DDP. In conclusion, this peptide nanodelivery system that transforms in response to the acidic tumor microenvironment is an extremely promising nanoplatform that suggests a new idea for the combined treatment of tumors.This article is protected by copyright. All rights reserved

show abstract

“…In addition, ncRNAs have gained interest as GC-targeted drugs for treating GC. Cisplatin (CDDP) chemotherapy significantly reduces the level of miR-30a in GC cells, and interestingly, up-regulation of miR-30a inhibits GC cell sensitivity to CDDP [164]. Furthermore, CDDP-resistant GC cells that up-regulated SNHG6 and circ_AKT3 expression could regulate CDDP Interaction with miR-206 regulates cisplatin resistance [168] resistance and GC progression via sponge miR-1297 and miR-206, respectively, indicating that targeting SNHG6 and circ_AKT3 may be a promising option to address GC chemoresistance [166,168].…”

Section: Clinical Application Of Ncrnas In Gc Liquid Biopsymentioning

confidence: 99%

Clinical application and detection techniques of liquid biopsy in gastric cancer

Zhou

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common tumors worldwide and the leading cause of tumor-related mortality. Endoscopy and serological tumor marker testing are currently the main methods of GC screening, and treatment relies on surgical resection or chemotherapy. However, traditional examination and treatment methods are more harmful to patients and less sensitive and accurate. A minimally invasive method to respond to GC early screening, prognosis monitoring, treatment efficacy, and drug resistance situations is urgently needed. As a result, liquid biopsy techniques have received much attention in the clinical application of GC. The non-invasive liquid biopsy technique requires fewer samples, is reproducible, and can guide individualized patient treatment by monitoring patients' molecular-level changes in real-time. In this review, we introduced the clinical applications of circulating tumor cells, circulating free DNA, circulating tumor DNA, non-coding RNAs, exosomes, and proteins, which are the primary markers in liquid biopsy technology in GC. We also discuss the current limitations and future trends of liquid biopsy technology as applied to early clinical biopsy technology.

show abstract

All-trans retinoic acid-mediated miR-30a up-regulation suppresses autophagy and sensitizes gastric cancer cells to cisplatin

Cited by 12 publications

References 40 publications

Deregulation of All-Trans Retinoic Acid Signaling and Development in Cancer

Deregulation of All-Trans Retinoic Acid Signaling and Development in Cancer

pH‐Triggered Transformable Peptide Nanocarriers Extend Drug Retention for Breast Cancer Combination Therapy

Clinical application and detection techniques of liquid biopsy in gastric cancer

Contact Info

Product

Resources

About